Introduction
Intrahepatic cholestasis is a rare but potentially fatal complication of sickle cell disease [1] . Sickle cell intrahepatic cholestasis (SCIC) is characterised by right upper quadrant pain, hepatomegaly and progressive hyperbilirubinaemia. To date 15 adult patients have been reported in the literature and only six survived [2] . We present a case of haemoglobin S/Beta thalassaemia with intrahepatic cholestasis successfully treated by partial exchange blood-plasma transfusion.
Case report
A 34-year old patient with haemoglobin S Beta thalassaemia presented with a three week history of jaundice and right hypochondrial pain. He did not complain of fever, anorexia or pruritus. There was no evidence of liver failure or chronic liver disease. Vital signs were normal. Sickle beta thalassaemia had been diagnosed at the age of 18 years and the patient had several episodes of haemolysis requiring blood transfusions. Investigations showed: haemoglobin 9.9 g/dl, WCC 10.810 9 /l, and platelets 40710 9 /l, AST/ALT 131/170 IU/l, alkaline phosphatase 294 U/l, total bilirubin 215 μmol/l (102 μmol/l conjugated), reticulocytes 17%. An ultrasound examination showed gall stones without evidence of cholecystitis or dilatation of intra-or extra-hepatic bile ducts. Serology for hepatitis B and C was negative. Over the ensuing week he developed nausea, anorexia and pruritus. Bilirubin rose to 632 μmol/l (513 μmol/l conjugated). Initial management included vitamin K, blood transfusions and empirical broad spectrum antibiotics. Liver biopsy was performed. Biliary canaliculi and sinusoids distended with bile, and ballooning degeneration of hepatocytes and focal necrosis were noted. Over the next two weeks the patient became progressively more icteric and drowsy, developing asterixis and coagulopathy. He had blood stained vomiting and melaena. Investigation at this stage showed: total bilirubin 992 μmol/l (889 μmol/l conjugated), INR 3.4, haemoglobin 7.5 g/dl, WCC 3510 9 /l, blood urea 37 mmol/l, AST/ALT 171/81 IU/l. Partial blood-plasma exchange transfusion was carried out. One unit of whole blood was removed and replaced with fresh frozen plasma (FFP) and one unit of cross-matched blood. This was done five times over the next 24 hours. The patient showed a dramatic improvement. Asterixis disappeared within 24 hours of exchange. By day six his total bilirubin had decreased to 359 μmol/l. His biochemistry continued to improve. After four weeks his bilirubin was 137 μmol/l.
Exchange transfusion for intrahepatic cholestasis due to sickle beta thalassaemia

Discussion
A review of liver disorders associated with sickle cell disease has identified five specific syndromes i.e., hepatic crisis, viral hepatitis, gall stones, cirrhosis and intrahepatic cholestasis [3] . SCIC has been reported in homozygous HbS sickle cell patients as well as in patients who are heterozygous for HbS and beta thalassaemia [2] . SCIC is rare but carries a grim prognosis. The aetiology remains unclear and the pathophysiology is poorly understood. SCIC is histologically characterised by intracanalicular cholestasis [4] .
Only six of fifteen previously reported adult patients had survived [2] . All six had undergone exchange transfusion. However, there are three reports of SCIC with a fatal outcome despite exchange transfusion [2, 5, 6] . In one report the patient was relatively older (48 years) and had hepatitis C and cirrhosis [2] . In the second report the patient expired two months after discharge from hospital and he had undergone two ERCPs and a liver biopsy prior to exchange [6] . The other fatal outcome was reported in a patient with advanced hepatic fibrosis who had a complicated trans-jugular liver biopsy which required surgical intervention [5] . All of them had advanced liver disease or had undergone an intervention or both prior to exchange transfusion. This may have contributed to the bad outcome in these patients. A series from England reported a 28% incidence of death following liver biopsy in patients with sickle cell disease associated with acute hepatic disease [7] . All forms of surgery including cholecystectomy, carry a high complication rate in these patients [8] .
The treatment of this potentially fatal complication is not universally accepted. Early exchange transfusion seems to be the most accepted and effective form of therapy. The aim of this therapy is to reduce and maintain the haemoglobin S level at less than 30%. Clinical improvement may result from the exchange transfusion of RBC or FFP or both [9] .
